A One Health approach to antimicrobial resistance surveillance: is there a business case for it?

International Journal of Antimicrobial Agents

Volumn 48, Issue 4, 2016, Pages 422-427

  Queenan, Kevin ^a   Häsler, Barbara ^a   Rushton, Jonathan ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

AMR; Antimicrobial resistance; Business case; Economics; One Health; Surveillance

Indexed keywords

ANIMAL WELFARE; ANTIBIOTIC RESISTANCE; ARTICLE; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG SEEKING BEHAVIOR; DRUG SURVEILLANCE PROGRAM; FOOD INDUSTRY; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MEASUREMENT ACCURACY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; ANIMAL; DRUG UTILIZATION; EPIDEMIOLOGICAL MONITORING; HEALTH;

ANTIINFECTIVE AGENT;

ANIMALS; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; EPIDEMIOLOGICAL MONITORING; GLOBAL HEALTH; HUMANS;

EID: 84988569256     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.06.014     Document Type: Article

References (40)

1. [1] World Health Organization, WHO global strategy for containment of antimicrobial resistance. 2001, WHO, Geneva, Switzerland.
2. [2] Taylor, J., Hafner, M., Yerushalmi, E., Smith, R., Bellasio, J., Vardavas, R., et al. Estimating the economic costs of antimicrobial resistance. 2014, RAND Europe, Santa Monica, CA.
3. [3] Smith, R., Coast, J., The true cost of antimicrobial resistance. BMJ 346 (2013), 1–5.
4. [4] European Commission, Action plan against the rising threats from antimicrobial resistance. Communication from the Commission to the European Parliament and the Council, Director General for Health and Consumers. 2011, European Commission, Brussels, Belgium.
5. [5] Transatlantic Taskforce on Antimicrobial Resistance (TATFAR), Progress report: recommendations for future collaboration between the US and EU. 2014, US Centers for Disease Control and Prevention (CDC), Atlanta, GA.
6. [6] O'Neill, J., (eds.) Review on antimicrobial resistance. Tackling a global health crisis: initial steps. Tacking drug-resistant infections globally, 2015, HM Government, London, UK.
7. [7] Critchley, I.A., Karlowsky, J.A., Optimal use of antibiotic resistance surveillance systems. Clin Microbiol Infect 10 (2004), 502–511.
8. [8] Grundmann, H., Klugman, K.P., Walsh, T., Ramon-Pardo, P., Sigauque, B., Khan, W., et al. A framework for global surveillance of antibiotic resistance. Drug Resist Updat 14 (2011), 79–87.
9. [9] Aryee, A., Price, N., Antimicrobial stewardship—can we afford to do without it?. Br J Clin Pharmacol 79 (2014), 173–181.
10. [10] World Health Organization, Antimicrobial resistance: global report on surveillance. 2014, WHO, Geneva, Switzerland.
11. [11] The White House, National action plan for combating antibiotic-resistant bacteria. 2015, The White House, Washington, DC.
12. [12] Zinsstag, J., Schelling, E., Waltner-Toews, D., Tanner, M., From ‘one medicine’ to ‘one health’ and systemic approaches to health and well-being. Prev Vet Med 101 (2011), 148–156.
13. [13] Kock, R., Structural One Health—are we there yet?. Vet Rec 176 (2015), 140–142.
14. [14] Rushton, J., Anti-microbial use in animals: how to assess the trade-offs. Zoonoses Public Health 62:Suppl. 1 (2015), 10–21.
15. [15] Center for Disease Dynamics, Economics & Policy (CDDEP), State of the world's antibiotics. 2015, CDDEP, Washington, DC.
16. [16] Rushton, J., Hasler, B., De Haan, N., Rushton, R., Economic benefits or drivers of a ‘One Health’ approach: why should anyone invest?. Onderstepoort J Vet Res, 79, 2012, 461.
17. [17] Häsler, B., Gilbert, W., Jones, B.A., Pfeiffer, D.U., Rushton, J., Otte, M.J., The economic value of One Health in relation to the mitigation of zoonotic disease risks. Curr Top Microbiol Immunol 365 (2013), 127–151.
18. [18] Grace, D., The business case for One Health. Onderstepoort J Vet Res 81 (2014), E1–6.
19. [19] Babo Martins, S., Rushton, J., Stark, K.D., Economic assessment of zoonoses surveillance in a ‘One Health’ context: a conceptual framework. Zoonoses Public Health 63 (2016), 386–395.
20. [20] Prescott, J.F., The resistance tsunami, antimicrobial stewardship, and the golden age of microbiology. Vet Microbiol 171 (2014), 273–278.
21. [21] Radhouani, H., Silva, N., Poeta, P., Torres, C., Correia, S., Igrejas, G., Potential impact of antimicrobial resistance in wildlife, environment and human health. Front Microbiol 5 (2014), 1–12.
22. [22] Butaye, P., van Duijkeren, E., Prescott, J.F., Schwarz, S., Antimicrobial resistance in bacteria from animals and the environment. Vet Microbiol 171 (2014), 269–272.
23. [23] European Centre for Disease Prevention and Control (ECDC); European Food Safety Authority (EFSA); European Medicines Agency (EMA), ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. EFSA J, 13, 2015, 4006.
24. [24] Shallcross, L.J., Davies, S.C., Antibiotic overuse: a key driver of antimicrobial resistance. Br J Gen Pract 64 (2014), 604–605.
25. [25] Giuliano, C.A., Rybak, M.J., Efficacy of triclosan as an antimicrobial hand soap and its potential impact on antimicrobial resistance: a focused review. Pharmacotherapy 35 (2015), 328–336.
26. [26] Mateus, A.L., Brodbelt, D.C., Barber, N., Stark, K.D., Qualitative study of factors associated with antimicrobial usage in seven small animal veterinary practices in the UK. Prev Vet Med 117 (2014), 68–78.
27. [27] Berendonk, T.U., Manaia, C.M., Merlin, C., Fatta-Kassinos, D., Cytryn, E., Walsh, F., et al. Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol 13 (2015), 310–317.
28. [28] European Medicines Agency (EMA); European Surveillance of Veterinary Antimicrobial Consumption (ESVAC), Sales of veterinary antimicrobial agents in 26 EU/EEA countries in 2012. 2014, EMA/ESVAC.
29. [29] Danish Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP), Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. 2013, DANMAP.
30. [30] Livermore, D.M., Macgowan, A.P., Wade, M.C.J., Surveillance of antimicrobial resistance: centralised surveys to validate routine data offer a practical approach. BMJ 317 (1998), 614–615.
31. [31] Rushton, J., Stärk, K., Pinto Ferreira, J., Antimicrobial resistance: the use of antimicrobials in the livestock sector. 2014, OECD Publishing, Paris, France.
32. [32] World Health Organization, Technical consultation: strategies for global surveillance of antimicrobial resistance. 2012, WHO, Geneva, Switzerland.
33. [33] Häsler, B., Cornelsen, L., Bennani, H., Rushton, J., A review of the metrics for One Health benefits. Rev Sci Tech Off Int Epiz 33 (2014), 453–464.
34. [34] The World Bank, People, pathogens and our planet. The economics of One Health. 2012, The World Bank, Agriculture and Rural Development, Health Nutrition and Population.
35. [35] Doyle, M.P., Loneragan, G.H., Scott, H.M., Singer, R.S., Antimicrobial resistance: challenges and perspectives. Compr Rev Food Sci Food Saf 12 (2013), 234–248.
36. [36] Jensen, H.H., Hayes, D.J., Impact of Denmark's ban on antimicrobials for growth promotion. Curr Opin Microbiol 19 (2014), 30–36.
37. [37] Institute of Medicine, Improving food safety through a One Health approach. 2012, The National Academies Press, Washington, DC.
38. [38] KPMG, The global economic impact of anti-microbial resistance. 2014, KPMG.
39. [39] Sosa, A.D.J., Amábile-Cuevas, C.F., Byarugaba, D.K., Hsueh, P., Kariuki, S., Okeke, I.N., Antimicrobial resistance in developing countries. 2010, Springer, New York, NY.
40. [40] Van Boeckel, T.P., Brower, C., Gilbert, M., Grenfell, B.T., Levin, S.A., Robinson, T.P., et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA 112 (2015), 5649–5654.